SMARCD1 and gastric cancer: Of particular clinical relevance, SMARCD1 is markedly upregulated in the gastric tissues of patients with gastric inflammation and also gastric cancer, and high SMARCD1 expression is associated with shorter patient survival, independent of TNM staging [27].